Helen J Curtis

Helen J Curtis

Auto-generated profile, based on publicly available information

Helen J Curtis

Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
EWElizabeth Williamson
Elizabeth Williamson
AWAlex J Walker
Alex J Walker
KBKrishnan J Bhaskaran
Krishnan J Bhaskaran
SBSeb Bacon
Seb Bacon
CBChris Bates
Chris Bates
BGBen Goldacre
Ben Goldacre
Background: Establishing who is at risk from a novel rapidly arising cause of death, and why, requires a new approach to epidemiological research with very large datasets and timely data. Working on behalf of NHS England we therefore set out to deliver a secure and pseudonymised analytics platform inside the data centre of a major primary care electronic health records vendor establishing coverage across detailed primary care records for a substantial proportion of all patients in England. The following results are preliminary. Data sources: Primary care electronic health records managed by the electronic health record vendor TPP, pseudonymously linked to patient-level data from the COVID-19 Patient Notification System (CPNS) for death of hospital inpatients with confirmed COVID-19, using the new OpenSAFELY platform. Population: 17,425,445 adults. Time period: 1st Feb 2020 to 25th April 2020. Primary outcome: Death in hospital among people with confirmed COVID-19. Methods: Cohort study analysed by Cox-regression to generate hazard ratios: age and sex adjusted, and multiply adjusted for co-variates selected prospectively on the basis of clinical interest and prior findings. Results: There were 5683 deaths attributed to COVID-19. In summary after full adjustment, death from COVID-19 was strongly associated with: being male (hazard ratio 1.99, 95%CI 1.88-2.10); older age and deprivation (both with a strong gradient); uncontrolled diabetes (HR 2.36 95% CI 2.18-2.56); severe asthma (HR 1.25 CI 1.08-1.44); and various other prior medical conditions. Compared to people with ethnicity recorded as white, black people were at higher risk of death, with only partial attenuation in hazard ratios from the fully adjusted model (age-sex adjusted HR 2.17 95% CI 1.84-2.57; fully adjusted HR 1.71 95% CI 1.44-2.02); with similar findings for Asian people (age-sex adjusted HR 1.95 95% CI 1.73-2.18; fully adjusted HR 1.62 95% CI 1.431.82). Conclusions: We have quantified a range of clinical risk factors for death from COVID-19, some of which were not previously well characterised, in the largest cohort study conducted by any country to date. People from Asian and black groups are at markedly increased risk of in-hospital death from COVID-19, and contrary to some prior speculation this is only partially attributable to pre-existing clinical risk factors or deprivation; further research into the drivers of this association is therefore urgently required. Deprivation is also a major risk factor with, again, little of the excess risk explained by co-morbidity or other risk factors. The findings for clinical risk factors are concordant with policies in the UK for protecting those at highest risk. Our OpenSAFELY platform is rapidly adding further NHS patients’ records; we will update and extend these results regularly.

18 July 2022 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
CAColm D Andrews
Colm D Andrews
ASAnna Schultze
Anna Schultze
HCHelen Curtis
Helen Curtis
WHWilliam Hulme
William Hulme
JTJohn Tazare
John Tazare
AWAlex Walker
Alex Walker
Background: Since its inception in March 2020, data from the OpenSAFELY-TPP electronic health record platform has been used for more than 20 studies relating to the global COVID-19 emergency. OpenSAFELY-TPP data is derived from practices in England using SystmOne software, and has been used for the majority of these studies. We set out to investigate the representativeness of OpenSAFELY-TPP data by comparing it to national population estimates. Methods: With the approval of NHS England, we describe the age, sex, Index of Multiple Deprivation and ethnicity of the OpenSAFELY-TPP population compared to national estimates from the Office for National Statistics. The five leading causes of death occurring between the 1st January 2020 and the 31st December 2020 were also compared to deaths registered in England during the same period. Results: Despite regional variations, TPP is largely representative of the general population of England in terms of IMD (all within 1.1 percentage points), age, sex (within 0.1 percentage points), ethnicity and causes of death. The proportion of the five leading causes of death is broadly similar to those reported by ONS (all within 1 percentage point). Conclusions: Data made available via OpenSAFELY-TPP is broadly representative of the English population. Users of OpenSAFELY must consider the issues of representativeness, generalisability and external validity associated with using TPP data for health research. Although the coverage of TPP practices varies regionally across England, TPP registered patients are generally representative of the English population as a whole in terms of key demographic characteristics.

12 October 2014 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
JTJennifer Y Tan
Jennifer Y Tan
KVKeith W Vance
Keith W Vance
MVMiguel A Varela
Miguel A Varela
TSTamara Sirey
Tamara Sirey
LWLauren M Watson
Lauren M Watson
AMAna C Marques
Ana C Marques
CAG-repeat expansion in the housekeeping gene ATXN7 causes the neurodegenerative disorder SCA7. Now ATXN7 protein is found to promote transcription and expression of miR-124, which in turn mediates cross-talk between lnc-SCA7 and ATXN7 transcripts. What causes the tissue-specific pathology of diseases resulting from mutations in housekeeping genes? Specifically, in spinocerebellar ataxia type 7 (SCA7), a neurodegenerative disorder caused by a CAG-repeat expansion in ATXN7 (which encodes an essential component of the mammalian transcription coactivation complex, STAGA), the factors underlying the characteristic progressive cerebellar and retinal degeneration in patients were unknown. We found that STAGA is required for the transcription initiation of miR-124, which in turn mediates the post-transcriptional cross-talk between lnc-SCA7, a conserved long noncoding RNA, and ATXN7 mRNA. In SCA7, mutations in ATXN7 disrupt these regulatory interactions and result in a neuron-specific increase in ATXN7 expression. Strikingly, in mice this increase is most prominent in the SCA7 disease-relevant tissues, namely the retina and cerebellum. Our results illustrate how noncoding RNA–mediated feedback regulation of a ubiquitously expressed housekeeping gene may contribute to specific neurodegeneration.

25 June 2012 in WIREs RNA
Verified
Journal Article
Closed access
PDF file
HCHelen J. Curtis
Helen J. Curtis
CSChristopher R. Sibley
Christopher R. Sibley
MWMatthew Wood
Matthew Wood

5 June 2018 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
HCHelen J. Curtis
Helen J. Curtis
JDJohn M. Dennis
John M. Dennis
BSBeverley M. Shields
Beverley M. Shields
AWAlex J. Walker
Alex J. Walker
SBSeb Bacon
Seb Bacon
BGBen Goldacre
Ben Goldacre
Aims: To measure the variation in prescribing of second‐line non‐insulin diabetes drugs. Materials and Methods: We evaluated time trends for the period 1998 to 2016, using England's publicly available prescribing datasets, and stratified these by the order in which they were prescribed to patients using the Clinical Practice Research Datalink. We calculated the proportion of each class of diabetes drug as a percentage of the total per year. We evaluated geographical variation in prescribing using general practice‐level data for the latest 12 months (to August 2017), with aggregation to Clinical Commissioning Groups. We calculated percentiles and ranges, and plotted maps. Results: Prescribing of therapy after metformin is changing rapidly. Dipeptidyl peptidase‐4 (DPP‐4) inhibitor use has increased markedly, with DPP‐4 inhibitors now the most common second‐line drug (43% prescriptions in 2016). The use of sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors also increased rapidly (14% new second‐line, 27% new third‐line prescriptions in 2016). There was wide geographical variation in choice of therapies and average spend per patient. In contrast, metformin was consistently used as a first‐line treatment in accordance with guidelines. Conclusions: In England there is extensive geographical variation in the prescribing of diabetes drugs after metformin, and increasing use of higher‐cost DPP‐4 inhibitors and SGLT‐2 inhibitors compared with low‐cost sulphonylureas. Our findings strongly support the case for comparative effectiveness trials of current diabetes drugs.

23 February 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
HCHelen J Curtis
Helen J Curtis
BGBen Goldacre
Ben Goldacre
Objectives We aimed to compile and normalise England’s national prescribing data for 1998–2016 to facilitate research on long-term time trends and create an open-data exploration tool for wider use. Design We compiled data from each individual year’s national statistical publications and normalised them by mapping each drug to its current classification within the national formulary where possible. We created a freely accessible, interactive web tool to allow anyone to interact with the processed data. Setting and participants We downloaded all available annual prescription cost analysis datasets, which include cost and quantity for all prescription items dispensed in the community in England. Medical devices and appliances were excluded. Primary and secondary outcome measures We measured the extent of normalisation of data and aimed to produce a functioning accessible analysis tool. Results All data were imported successfully. 87.5% of drugs were matched exactly on name to the current formulary and a further 6.5% to similar drug names. All drugs in core clinical chapters were reconciled to their current location in the data schema, with only 1.26% of drugs not assigned a current chemical code. We created an openly accessible interactive tool to facilitate wider use of these data. Conclusions Publicly available data can be made accessible through interactive online tools to help researchers and policy-makers explore time trends in prescribing.